Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19451794 | 1.00 | STING1 (0.91) | STING1CYP3A4 | |
| Hydrochloric Acid SCHEMBL29619888 | 0.99 | STING1 (0.90) | STING1CYP3A4 | |
| SCHEMBL19451487 | 0.97 | STING1 (0.94) | STING1CYP3A4 | |
| SCHEMBL19451735 | 0.97 | STING1 (0.85) | STING1CYP3A4 | |
| SCHEMBL23077369 | 0.95 | STING1 (0.83) | STING1CYP3A4 | |
| SCHEMBL23077371 | 0.95 | STING1 (0.83) | STING1CYP3A4 | |
| SCHEMBL23327842 | 0.95 | STING1 (1.00) | STING1CYP3A4 | |
| SCHEMBL22151651 | 0.95 | STING1 (0.89) | STING1CYP3A4 | |
| SCHEMBL29626047 | 0.95 | STING1 (1.00) | STING1CYP3A4 | |
| SCHEMBL19451558 | 0.95 | STING1 (1.00) | STING1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11970480-B2 | Heterocyclic amides useful as protein modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-04-30 | — | — | US | disclosed |
| US-20230071675-A1 | Heterocyclic Amides Useful as Protein Modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-03-09 | — | — | US | disclosed |
| US-11365190-B2 | Heterocyclic amides useful as protein modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-06-21 | — | — | US | disclosed |
| EP-3440076-B1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-06-01 | — | — | EP | disclosed |
| CN-113549110-A | Heterocyclic amides as protein modulators | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-10-26 | — | — | CN | disclosed |
| CN-109608443-B | Heterocyclic amides as protein modulators | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-09-07 | — | — | CN | disclosed |
| US-20210238172-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS AND METHODS OF USING THE SAME | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-05 | — | — | US | disclosed |
| CN-109071514-B | Heterocyclic amides as protein modulators | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-07-06 | — | — | CN | disclosed |
| US-20210139473-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| US-10981901-B1 | Heterocyclic amides useful as protein modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-20 | — | — | US | disclosed |
| EP-3692033-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) USEFUL IN TREATING HIV | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-08-12 | — | — | EP | disclosed |
| WO-2019069269-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) USEFUL IN TREATING HIV | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11970480-B2 | Heterocyclic amides useful as protein modulators | RB1, RBBP5, RCC2 | STING1 3127/4885CYP3A4 4195/4885 |
| US-11365190-B2 | Heterocyclic amides useful as protein modulators | RB1, RBBP5, RCC2 | STING1 3127/4885CYP3A4 4195/4885 |
| US-20210238172-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS AND METHODS OF USING THE SAME | AADAC, TAF15, HDAC10 | STING1 748/4885CYP3A4 3022/4885 |
| US-20210139473-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | RB1, RBBP5, RCC2 | STING1 3127/4885CYP3A4 4195/4885 |
| US-20230071675-A1 | Heterocyclic Amides Useful as Protein Modulators | RB1, RBBP5, RCC2 | STING1 3127/4885CYP3A4 4195/4885 |
| US-10981901-B1 | Heterocyclic amides useful as protein modulators | RB1, RBBP5, RCC2 | STING1 3127/4885CYP3A4 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.